MedTrace Logo

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

NCT05239182 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2025-07-17

Study results available
· View outcomes & findings →

Summary

This trial examines how Pancreatic Adenocarcinoma reacts to the addition of 9-ING-41 and retifanlimab to the standard of care chemotherapy treatment, to see if using this combination will help and is able to effect disease progression.

Conditions

  • Pancreatic Adenocarcinoma

Interventions

DRUG

9-ING-41

9-ING-41 is a small molecule potent selective GSK-3β inhibitor

DRUG

Retifanlimab

Humanized, hinge-stabilized, IgG4κ monoclonal antibody that recognizes human PD-1.

DRUG

Gemcitabine

cytotoxic chemotherapy agent

DRUG

Abraxane

cytotoxic chemotherapy agent

Sponsors & Collaborators

  • Actuate Therapeutics Inc.

    collaborator INDUSTRY

  • Incyte Corporation

    collaborator INDUSTRY

  • Anwaar Saeed

    lead OTHER

Principal Investigators

  • Anwaar Saeed, MD · University of Pittsburgh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-26
Primary Completion
2022-12-20
Completion
2024-02-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05239182 on ClinicalTrials.gov